RBC Capital Reiterates Outperform on Legend Biotech, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Legend Biotech (NASDAQ:LEGN) and maintained a price target of $85.
March 12, 2024 | 3:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating and a $85 price target on Legend Biotech.
The reiteration of an Outperform rating and maintenance of a high price target by a reputable analyst like Leonid Timashev from RBC Capital could instill confidence among investors and potentially lead to a positive short-term impact on Legend Biotech's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100